The initial production of inflammatory mediators dictates host defense as well as tissue injury. Inflammasome activation is a constituent of the inflammatory response by recognizing pathogen and host-derived products and eliciting the production of IL-1β, IL-18 as well as inducing a type of inflammatory cell death termed "pyroptosis". Leukotriene B4 (LTB4) is a lipid mediator produced quickly (seconds to minutes) by phagocytes and induces chemotaxis, enhances cytokine/chemokine production, and enhances antimicrobial effector functions.
Introduction
Upon infection, a quick and highly synchronized inflammatory response is mounted to restrict microbial growth and eventually eliminate the pathogen. Therefore, studies focusing on early events could unmask new players involved in the generation and magnitude of the host defense. Inflammasomes are multiprotein, intracellular platforms that detect both pathogen and host-derived products and induce the inflammatory response. The proteins that form the inflammasome consist of upstream sensors that belong to the NOD-like receptor (NLR) family, the adaptor protein, Apoptosis-Associated Speck-Like Protein Containing CARD (ASC), and the downstream effector caspase-1. There are different NLR proteins, including NLRP1, 2, 3, 6, 7, and NLRC4, as well as interferon-inducible protein (AIM2) (1, 2) . The different NLRs recognize both distinct and overlapping stressors to elicit the maturation and secretion of the inflammatory cytokines IL-1β and IL-18. Upon cell stimulation with either pathogen - (PAMPs) or damage (DAMPs)-associated molecular patterns, the inflammasome is activated in two sequential steps: 1) transcription of the long forms of IL-1β and IL-18, and 2) the assembly of the inflammasome complex ASC/NLRP and pro-caspase-1and subsequentially autocatalytic cleavage of caspase-1 and processing and secretion of IL-1 and IL-18, as well as production of lipid mediators such as prostaglandins and leukotriene B4 (LTB4) (3) (4) (5) . The secretion of these cytokines is followed by a form of programmed cell death called pyroptosis that releases DAMPs and further amplifies the inflammatory response. Increased production of IL-1β and IL-18, along with DAMPs generation, have been heavily implicated in the pathogenesis of a myriad of inflammatory diseases and facilitates antimicrobial activities (1, 6) .
Staphylococcus aureus skin infection is controlled by the synchronized actions of structural cells (keratinocytes) and skin phagocytes. Inflammasome-dependent IL-11β production is required for neutrophil recruitment, abscess formation, and bacterial clearance (7, 8) . The mechanisms underlying inflammasome activation and IL-11β production during skin infection is not well understood.
Staphylococcus aureus skin infection is controlled by the synchronized actions of structural cells (keratinocytes) and skin phagocytes (7, 8) . Inflammasome-dependent IL-1β production is required for neutrophil recruitment, abscess formation, and bacterial clearance (9) . The mechanisms underlying inflammasome activation and IL-1β production during skin infection is not well understood.
LTB4 is a bioactive lipid mediator quickly produced by phagocytes, such as macrophages and neutrophils. LTB4 synthesis involves several rate-limiting steps that include activation of phospholipase A2 (PLA2) and arachidonic acid (AA) release from phospholipids in cellular membranes. Activation of 5-LO and 5-LO activation protein (FLAP) together metabolize AA to LTA4, which is converted to LTB4 by LTA4 hydrolase (LTA4H) (10) . LTB4 binds to two different G protein-coupled receptors (GPCR). LTB4 receptor 1 (BLT1) is a highaffinity receptor, and BLT2 has a low affinity to LTB4 (11) . LTB4 via BLT1 enhances inflammatory response by increasing phagocyte chemotaxis, activation of transcription factors required for the production of inflammatory cytokines. LTB4 is required for the control of a myriad of pathogens. We and others have shown that LTB4NFκB and AP1 and PU.1). LTB4 also amplifies pattern recognition response (PRR) by increasing the expression of the TIR adaptor MyD88.NF-κ B and AP-1 and PU.1 ) (12) (13) (14) (15) . LTB4 also amplifies PRRs response by increasing the expression of the TIR adaptor MyD88 (15) . LTB4 is required for the control of a myriad of pathogens. We and others have shown that enhances microbial clearance by controlling the generation of reactive oxygen and nitrogen species, as well as antimicrobial peptides in vivo (16) (17) (18) (19) . We also have shown that the treatment of mice with a topical ointment containing LTB4 enhances S. aureus clearance, production of inflammatory mediators, and abscess formation (20) . Whether LTB4 enhances skin host defense directly or by indirectly increasing production of proinflammatory mediators remains to be determined. Also, whether influences inflammasome activation is poorly understood. It has been shown that LTB4mediated arthritis severity and increased leishmanicidal activity is impaired in ASC -/and NLRP3 -/mice (21, 22) . However, the mechanisms underlying LTB4-mediate inflammasome activation and whether LTB4 is a component of the IL-1β-mediated skin host defense remains to be elucidated. Here, using epistatic and gain of function approaches, we are showing that LTB4 is required for both first and second signals required for inflammasome activation and identified critical signaling programs required for inflammasome assembly, IL-1β secretion and its consequences in skin host defense.
Methods

Animals
Mice were maintained according to National Institutes of Health guidelines for the use of experimental animals with the approval of the Indiana University (protocol #10500) and
Vanderbilt University Medical Center (protocol #M1600154) Committees for the Use and Care of Animals. Experiments were performed following the United States Public Health Service Policy on Humane Care and Use of Laboratory Animals and the US Animal Welfare Act.
Eighteen-week-old female or male BLT1 -/-(B6.129S4-Ltb4r1 tm1Adl /J(23), LysMcre, MMDTR, and strain-matched WT C57BL/6 mice were purchased from Jackson Labs (Bar Harbor, ME USA). EGFP-LysM was donated by Dr. Nadia Carlesso (City of Hope, Duarte, CA, USA), and the pIL1DsRed (donated by Dr. Akiko Takashima, University of Toledo, Toledo, OH, USA (24) .
Primary cell isolation and culture
Murine resident peritoneal macrophages were isolated using ice-cold phosphate-buffered saline (PBS) as previously described (15, 25) . To isolate neutrophils, bone marrow from both tibias and femurs were flushed with phosphate-buffered saline (PBS) (20) 
Inflammasome activation
Macrophages and neutrophils were challenged with 100ng/mL LPS for 3h, followed by treatment with Nigericin 1μM (1h), Monosodium Urate Crystal (MSU -10μM), Flagellin 20μg/mL, and Poly(dA:dT)/LyoVec 2μg/mL for 3h. To assess the role of LTB4 in amplifying inflammasome activity, cells were treated with 100 nM LTB4 or 1 μM BLT1 antagonist U-75302 5 minutes before the addition of the inflammasome activators. The direct effect of LTB4 in inflammasome activation was studied in cells treated with LPS as above, followed by LTB4 for 3h.
MRSA skin infection and topical ointment treatment
Mice were infected with MRSA USA300 LAC strain (~3 ×10 6 colony-forming units [CFU]) s.c.
in 50μL of PBS as previously shown (26) . Lesion and abscess sizes were monitored and determined by affected areas calculated using a standard formula for the area: (A = [π/2] × l × w) (27) . The final concentrations of the ointments were as follows: LTB4 (33.7 ng-3.37 × 10 −6 %), U-75302 (0.001%), all in 1g of petroleum jelly (vehicle control). The treatments were applied to the infected area with a clean cotton swab. Mice were treated once a day throughout infection (ranging from 6 hours to 9 days).
Skin biopsies and bacterial load
Punch biopsies (8 mm) from noninfected (naïve) or infected skin were harvested at different time points and used for determining bacterial counts, cytokine production, RNA extraction, cell isolation, histological analyses, and proximity ligation assay (PLA) staining (28) . For bacterial load, skin biopsies were collected on day nine post-infection, processed and homogenized in tryptic soy broth (TSB) medium. Serial dilutions were plated on TSB agar plates, and colonies were incubated at 37ºC, 5% CO2 and counted after 18h. Bacterial burdens were normalized to tissue weight and calculated by the following equation: ((CFU/mL plated)*(dilution factor))/(tissue weight in mg). Bacterial burdens in the skin are represented by CFU/mg tissue (26) .
Quantitative real-time PCR (qPCR)
Total RNA was isolated from cultured macrophages or skin biopsies using lysis buffer (RLT;
Qiagen, Redwood City, CA, USA). The RT 2 First Strand Kit reverse transcription system (QIAGEN) was used for cDNA synthesis, and quantitative PCR (qPCR) was performed on a CFX96 Real-Time PCR Detection System (Bio-Rad Laboratories, CA, EUA). Gene-specific primers were purchased from Integrated DNA Technologies (Redwood City, CA, USA).
Relative expression was calculated as previously described (29) .
Immunoblotting
Western blots were performed as previously described (13) . Cell supernatants and cell lysate were collected, and proteins were precipitated using trichloroacetic acid (TCA). Cell lysate and supernatant were resolved by SDS-PAGE, transferred to a nitrocellulose membrane, and probed with commercially available primary antibodies against caspase-1, IL-1β, ASC (all at 1:1000; Abcam) phosphorylated BTK (Tyr223), total BTK (all at 1:1000; Cell Signaling Technology, Danvers, MA, USA) or β-actin (1:10,000; Sigma-Aldrich, San Luis, Missouri, EUA). Densitometric analysis was performed as described previously (13) .
ELISA assays
Skin biopsy sections were homogenized with a pestle in TNE cell lysis buffer containing 1× protease inhibitor (Sigma-Aldrich, St. Louis, MO, USA) and centrifuged to pellet the cellular debris. The supernatant of cultured macrophages or skin lysate from WT or BLT1 -/mice were also used to detect IL-1β, TNF-α or caspase-1 by ELISA (Biolegend Inc., San Diego, CA, EUA).
Confocal microscopy and proximity ligation assay (PLA)
PLA was done using Duolink PLA kit (Sigma)in skin sections of naïve and infected WT and BLT1 -/mice or in vitro in peritoneal macrophages, and bone marrow neutrophils cultured in 8well chambered cell culture slides (Corning Inc., Nova York, EUA). In vitro, phagocytes were challenged with LPS or GFP-MRSA at MOI 50:1 for 3h and pretreated with 10μM BLT1 antagonist U-75302 or 10nM LTB4 for 15 min, followed by inflammasome activation (MSU or nigericin), for 1 hour. For in vivo PLA detection, WT mice (treated or not with an ointment containing LTB4) or BLT1 -/were injected s.c. with MRSA for 24h. Skin biopsies were collected for histological analyses and 8μm paraffin-embedded skin sections were used. Cells and skin sections were fixed with 4% formaldehyde for 10 minutes and permeabilized with 0.2% Triton X-100 in tris-buffered saline (TBS) for 10 min. Cells or tissues were then blocked with 1% bovine serum albumin and 10% normal donkey serum in TBS for 1 hour at room temperature and incubated with the indicated primary antibody pairs (ASC versus caspase1 or ASC versus pBTK (Tyr223)) overnight at 4°C. Oligonucleotide-conjugated secondary antibodies (PLA probe MINUS and PLA probe PLUS) against each of the primary antibodies were applied, and ligation and amplification were performed to produce rolling circle products. These products were detected with fluorescently labeled oligonucleotides, and the samples were counterstained with Duolink Mounting Medium with DAPI.
Cells were imaged on a Zeiss LSM 510 confocal microscope with an inverted Axiovert 100 M microscope stand using a C-apochromat 40×/1.2 W corr. Confocal images were taken with identical settings to enable comparison of staining. Z-stacked sections (10 to 22 slices) of the cells were captured in multitrack, and ImageJ software (NIH, Maryland, EUA) was used to reconstruct the images using the Z project plug-in (30, 31) . The extent of association between the inflammasome components, as well as their intracellular localization, was quantitated using the JaCoP plug-in for ImageJ (30) . The background of the collected images was corrected by the ImageJ rolling ball algorithm plug-in. For each experiment, at least 100 randomly selected cells or 10 field areas were scored.
Skin biopsy dissociation for flow cytometry
Skin biopsies were digested with collagenase D (Sigma-Aldrich) and processed to obtain a single-cell suspension, as previously described (26) . Single cells were stained with the different fluorescent antibodies (as indicated in the figure legends) and DsRed on the BD LSR II flow cytometer (BD Biosciences, San Jose, CA, USA). Analyses were completed using FlowJo analysis software (FlowJo, LLC., Ashland, OR, USA). 
IVIS in vivo imaging
Statistical analysis
Data analysis were performed in GraphPad Prism software (GraphPad Prism Software Inc., San Diego, CA). The statistical tests used are listed in the figure legends. Briefly, Student's ttest was used to compare two experimental groups. One-way ANOVA, followed by Tukey multiple comparison correction, was used to compare three or more groups. Two-way ANOVA with repeated measured, followed by Tukey multiple comparison correction, was used to compare infection areas over time between two or more mouse groups. P values < 0.05 were considered significant.
Results
LTB4/BLT1 axis promotes IL-1β production
LTB4 enhances the production of IL-1β during inflammatory conditions. Furthermore, LTB4 alone or in combination with cytokines and PAMPs activate different transcription factors that further enhance expression of Il1b mRNA expression (32, 33) . However, whether LTB4 enhances IL-1β abundance by increasing Il1b transcripts or IL-1β processing/maturation via effects on inflammasome activation is not known. Here, we measured Il1b transcripts and protein by ELISA in skin biopsy homogenates from uninfected and MRSA-infected mice. Skin biopsies from WT mice treated topically with LTB4 or the BLT1 antagonist U-75302 (20) , as well as Ltb4r1 -/mice collected from uninfected skin and day 1 post-MRSA infection revealed that topical LTB4 increased IL-1β and that both BLT1 antagonist treatment and Ltb4r1 -/showed decreased IL-1β protein and Il1b mRNA transcripts during infection compared to WT mice ( Figure 1A and B) . These data suggest that exogenous LTB4 (treated topically) enhances inflammasome-dependent IL-1β and endogenously produced LTB4 during skin infection is required for optimal IL-1β generation. Next, we aimed to determine whether LTB4 could also amplify IL-1β production in human neutrophils. Here, cells were treated with LPS for 3h, followed by LTB4 treatment. Our data show that LTB4 effects also extends to human neutrophils (Figure 1F) .
IL-1β is produced as a pro-cytokine, which requires gene expression and caspase-1 dependent maturation (34) . MRSA skin infection induced expression of Il1b (Figure 1A) .
MRSA-infected mice treated with LTB4 ointment did not significantly alter Il1b expression;
however, BLT1 antagonist U-75302 treatment blunted Il1b expression during MRSA skin infection. ELISA data confirmed that IL-1β is produced in the skin of mice during MRSA skin infection and that LTB4 treatment increased levels of IL-1β ( Figure 1B) . Increased levels of IL-1β despite no differences in gene expression suggest that LTB4 may be involved in promoting IL-1β processing.
To determine whether LTB4 influences the kinetics of IL-1β during MRSA skin infection, we employed the IL-1β reporter mouse pIL1DsRED using IVIS in vivo imaging technology.
The pIL1DsRED mice were infected with MRSA and treated with a topical ointment containing BLT1 antagonist U-75032 or vehicle control. Mice were imaged by IVIS for DsRed signal everyday post-infection for 5 days ( Figure 1C ). DsRed signal was highest at days 1 and 2 post-infection and decreased by day 3 of infection ( Figure 1C ). This suggests that IL-1β is expressed early during MRSA skin infection. BLT1 antagonist treatment showed minimal expression of DsRed at all points measured during infection, indicating that LTB4 was necessary for IL-1β expression during MRSA skin infection.
Furthermore, the specific effect of LTB4/BLT1 in Il1b mRNA expression was evidenced by the fact that neither exogenous LTB4 or BLT1 antagonist influences TNF-α expression and secretion in macrophages (Supplementary Fig. 1 A and B) . Moreover, we did not detect differences in TNF-α production after infection in the skin biopsy from Ltb4r1 -/mice ( Figure   1E ). Pharmacological and genetic BLT1 inhibition showed lower levels of IL-1β at day 1 post-MRSA skin infection than WT mice.
Next, we aimed to identify in which cells BLT1 is necessary for IL-1β production during MRSA skin infection. The pIL1DsRED mice were infected with MRSA and treated with or without BLT1 antagonist U-75302. BLT1 antagonist treatment did not alter the overall percent of macrophages (F4/80+ cells) in the skin during MRSA skin infection (Supplementary Figure   2A) ; however, the percent of macrophages expressing Il1b (DsRed + ) was significantly lower in the skin of BLT1 antagonist-treated mice than macrophages in the skin of untreated mice (Supplementary Figure 2B) . Not only the percent of total F4/80 + macrophages expressing
DsRed was reduced with BLT1 antagonist treatment, but also the mean fluorescence intensity (MFI) of DsRed was reduced in cells expressing DsRed (Supplementary Figure 2C) . BLT1
antagonism decreased the number of global Ly6G + neutrophils but did not reduce the numbers of DsRed expressing PMNs (Supplementary Figure 2D) . Importantly, the MFI of DsRed was lower in mice treated with BLT1 antagonist ( Supplementary Figure 2E and F) ,
indicating that BLT1 activation was not required for PMN migration to the infected skin, but rather, necessary for PMN IL-11β expression.
LTB4 enhances NLRP3 inflammasome activity
We then tested whether LTB4 controlled IL-1β processing through inflammasome assembly and caspase-1 activation. To determine inflammasome assembly, bone marrowderived neutrophils were imaged by fluorescence microscopy to determine associations of NLRP3 and ASC using PLA, and the close proximity of these proteins resulted in red fluorescence. Neutrophils with no treatment did not show interactions between NLRP3 and ASC (Figure 2A) . Neutrophils co-cultured with MRSA induced minimal, but significant, inflammasome assembly. Nigericin-induced inflammasome activation resulted in high NLRP3/ASC association compared to vehicle only. While LTB4 treatment further promoted, the BLT1 antagonist U-75302 treatment inhibited inflammasome assembly (Figure 2A) . To confirm these data, we used another inflammasome activator, MSU in peritoneal macrophages from WT or BLT1 -/mice; BLT1 -/macrophages treated with LPS plus MSU induced less inflammasome assembly than WT macrophages (Figure 2B) .
These findings were confirmed as we observed decreased active caspase-1 and mature IL-1β in the supernatant of macrophages treated with BLT1 antagonist and increased IL-1β in LTB4 treated cells ( Figure 2C ). Next, we aimed to investigate whether LTB 4LTB4 effects are restricted to NLRP3 or also enhance the activation of the AIM2 or NLRC4 inflammasome. Macrophages were challenged with LPS, followed by LTB4 and the AIM2 activator (Poly(dA:dT)/LyoVec) or the NLRC4 agonist (flagellin). In all circumstances, LTB4
further increased IL-1β abundance when macrophages were challenged with these other inflammasome activators (Figure 2D) . Also, murine macrophages and human neutrophils treated with LTB4 alone showed increased active caspase-1 when compared to cells treated with inflammasome activators. Then, we studied whether LTB4 itself drives the second signal to activate inflammasome and induce IL-1β secretion. Here, macrophages were treated with LPS as above, followed by LTB4 for 3h. We detected IL-1β increased in the supernatant of macrophages treated with LPS plus LTB4 when compared to LPS or LTB4 alone. Furthermore, increased IL-1β in the supernatant correlated with enhanced levels of active caspase-1 (Figure 2E) . That LTB4 itself enhances inflammasome activation was also evidenced in human neutrophils ( Figure 2F) . These results suggest that LTB4/BLT1 is necessary for Il1b expression and that LTB4 may be an essential mediator in regulating inflammasome assembly and activation, allowing for mature IL-1β production.
Next, we were poised to test the role of LTB4 in inflammasome activation in vivo.
Initially, we challenged WT and BLT1 -/mice with MSU, i.p, and 24h later we detected lower IL-1β in the peritoneal lavage of BLT1 -/mice than WT mice challenged with MSU ( Figure 3A) .
We then determined whether LTB4 production is required for inflammasome activation during MRSA skin infection. WT mice were challenged with MRSA s.c., followed by topical treatment with LTB4, as we have previously shown (20) . Our data show that while MRSA skin infection increases the abundance of both IL-1β and caspase-1, topical LTB4 further enhances IL-1 β secretion and caspase-1 activation in skin lysates ( Figure 3B) . Importantly, we confirmed the role of BLT1 in inflammasome activation in vivo in skin sections stained for the association between ASC/caspase-1 using PLA. Our data showed decreased ASC/caspase-1 interaction in areas near the abscess in MRSA-infected BLT1 -/mice when compared to infected WT mice ( Figure 3C) .
Together, these data show that endogenously produced LTB4 during inflammatory response or skin infection is required for both first and second signals for inflammasome activation.
LTB4/BLT1 axis enhances BTK-mediated inflammasome activation
Inflammasomes are controlled by a variety of post-translational modifications, including phosphorylation (35) . Here, we tested the role of different kinases known to be both activated by LTB4 and, involved in inflammasome activation (35) . Macrophages were challenged with LPS, followed by the indicated inhibitors (see legend), LTB4, and then nigericin. Our data show that only the BTK inhibitor (ibrutinib), but not PI3K, PKC, and Syk inhibitors prevented LTB4-mediated enhanced IL-1β production, (Figure 4A) . The role of BTK, but not other kinases in LTB4-mediated inflammasome activation was further confirmed by detecting active caspase-1 in the cell supernatant by immunoblotting ( Figure 4B) .
Whether LTB4 activates BTK remains to be determined. Here, we assessed the role of BLT1 in BTK phosphorylation and expression during MRSA skin infection. Our data clearly show that BTK is activated during MRSA infection and that LTB4/BLT1 signaling is required for optimal BTK phosphorylation in the skin (Figure 4C) . Given the role of LTB4 in BTK actions, we aimed to identify whether LTB4 would enhance BTK and ASC association in vivo. Using PLA to show protein interaction, our data unveiled that MRSA skin infection leads to enhanced phosphorylated BTK and ASC interaction, and importantly, topical LTB4 treatment further increased ASC/BTK association (Figure 4D) . In summary, we are showing that LTB4 is required for different steps of inflammasome activation by increasing transcriptional programs, as well as increasing phosphorylation of ASC and increasing speck formation.
Crosstalk between LTB4 and IL-1 to enhance skin host defense.
To demonstrate whether LTB4 is also involved in IL-1β-mediated skin host defense, we performed "add-back" experiments, by injecting WT and BLT1 -/mice with recombinant IL-1β s.c at the moment of infection. Our data show that IL-1β increases bacterial load and decreases lesion size in BLT1 -/mice (Figure 5 A) . Interestingly, IL-1β decreases bacterial load in WT mice but increases lesion size (as evidenced by elevated inflammatory response) (Figure 5 B) . Together, these data show that LTB4 production is a crucial component of IL-1β effects during skin bacterial clearance.
Discussion:
Inflammasome activation is a critical component of both host defense and inflammatory responses. Multiple regulatory programs enhance inflammasome activation, including enhancing transcriptional programs, ROS production, acetylation, ubiquitination and phosphorylation (35) . However, the signals that trigger upstream kinase activation and amplifies inflammasome assembly remains to be fully determined. Here, we are moving the field forward by identifying a regulatory program that amplifies both first and second signal required for optimal inflammasome activation and IL-1β production. Our data show that 1) genetic and pharmacologic LTB4/BLT1 actions promotes macrophage pro-Il1b mRNA expression in vivo and in vitro; 2) exogenous LTB4 enhances inflammasome-dependent IL-1β secretion; 3) Both exogenous and endogenous LTB4 enhances active caspase-1 and mature IL-1β in the supernatant of macrophages and neutrophils from both mice and humans; 4) LTB4 increases NLRP3 inflammasome assembly in a manner dependent on BTK phosphorylation; and 5) LTB4/BLT1 signaling is required for IL-1β-dependent MRSA skin host defense.
LTB4 participates in the initiation, potency, maintenance, and endurance of the inflammatory response by regulating the actions of different immune cells (36) . LTB4 is a potent inflammatory mediator that has long known to be a robust neutrophil chemoattractant (37, 38) . More recently, new roles for LTB4 in phagocyte biology has emerged.
We and others have shown that LTB4 is required for phagocytosis and antimicrobial effector functions by increasing reactive oxygen and nitrogen species secretion and defensin production during infection by gram-positive and negative bacteria, protozoan parasites, and viruses (16) (17) (18) (19) 39) . Although LTB4 is an essential homeostatic mediator of the inflammatory response, high and sustained LTB4 production has been associated with inflammatory diseases and metabolic dysfunctions (36, 40) , supporting the idea that abundant and chronic circulating LTB4 levels are harmful to the host. Moreover, exaggerated LTB4 is responsible for an aberrant TNF- production that drives susceptibility to mycobacterial infection in a zebrafish model. Also, a gain-of-function single-nucleotide polymorphism in the LTA4H gene is associated with susceptibility to tuberculosis in humans (41, 42) . Furthermore, we also have shown that during reduced skin infection in diabetic mice is characterized by an overwhelming inflammatory response, characterized by abundant LTB4 and IL-1β production and that blocking BLT1, but not BLT2 restores IL-1β to basal levels in the infected skin (43) . We also have shown that blocking LTB4 synthesis shows beneficial effects in a model of CLP-induced sepsis in diabetic mice by decreasing IL-1β IL-1β production and MyD88 expression (29) .
Here, we are further showing that blocking BLT1 in NLRP3 inflammasome-activated macrophage from diabetic mice inhibited caspase-1 activation (Supplementary Figure 3) .
Although we and others have shown that IL-1β participates in detrimental LTB4
responses, whether LTB4 differently regulates the first and/or the second signal required for inflammasome-dependent IL-1β maturation is unknown. LTB4-induced IL-1β production and NLRP3 inflammasome activation has been shown during Leishmania amazonensis infection . (44) and in a model of arthritis (21, 22) . However, to date, no mechanistic studies have been done to address this critical question.
We and others have shown that LTB4 controls the expression and actions of different PRRs, oxidant generation, protease release, and activation of inflammatory transcription factors (13, 14, (31) (32) (33) 45) . LTB4 increases NF-κB activation that could, in turn, enhance IL-1β, NLRP3, and caspase-1 expression. Here, using a reporter mouse that detects IL-1β (3, 13) . Here, using a reporter mouse that detects expression (IL1bDsRed), we are showing that BLT1 antagonism inhibits Il1b transcription in both macrophages and neutrophils at the peak of expression post-infection. This effect was restricted to IL-1β since we did not witness an effect of topical LTB4 or BLT1 antagonist in TNF-α production in macrophages during MRSA skin infection. Since NF-B controls the expression of both IL-1β and TNF-α, the specific mechanisms underlying the effects of LTB4 in IL-1β actions remain to be determined.
We and others have shown that the LTB4/BLT1 axis either directly induces or further amplifies the activation of different kinases, shaping cellular responses in different environments (45) (46) (47) . The inflammasome is activated by signals derived from pathogen products and host-derived molecules (DAMPs). Here, we are expanding the list of endogenous molecules that activate inflammasome, e.g., LTB4. However, the novelty of our work stems from the fact that LTB4 is not secreted by dying cells. LTB4 is produced quickly (seconds to minutes) after cell activation and therefore, could further amplify the signals required for inflammasome assembly. Here, we showed that LTB4 amplifies the effects of different NLRP3 agonists as well as induce inflammasome assembly directly. We then determined the events by which LTB4 enhances NLRP3 inflammasome assembly.
Given the role of BLT1 in activating a myriad of kinases, including ones known to enhance inflammasome activation (48) (49) (50) , we tested the role of BLT1 in the NLRP3 inflammasome assembly. Our data show that BLT1 activation is required for both in vivo and shown that PGE2/Eprostanoid receptor (EP) enhances PKA-dependent NLRP3 phosphorylation in macrophages. PGE2/PKA signaling is dictated by Gas-dependent cAMP production (3, 51) .
We and others have shown that BLT1 is coupled to both Gαi and Gαq that inhibits cAMP and increases Ca 2+ mobilization, respectively (15, 52, 53) . Importantly, GPCRs that are coupled to either Gαi or Gαq are also known to activate the inflammasome, by directly modulating the abundance of second messengers, or by influencing kinase-mediated inflammasome association. Although we did not investigate the role of different G proteins in BLT1-mediated inflammasome activation and the role of downstream effectors, the fact that neither PI3K or PKC-δ inhibition prevented LTB4-mediated inflammasome activation, suggests that Gαi-dependent decreased cAMP might be allowing inflammasome assembly. Whether cAMP influences BTK activation remains to be determined.
Here, we provided evidence that LTB4/BLT1/BTK phosphorylation is required for NLRP3/ASC assembly in phagocytes. Our data show that LTB4-mediated BTK1 phosphorylation is needed for the NLRP3/ASC association during inflammasome activation as well as during MRSA skin infection. BTK is a tyrosine kinase known to be necessary for B cell receptor and FcR signaling (54) . More recently, the role of BTK in phagocytes has emerged. BTK activation is required for TLR signaling, phagocyte recruitment to the inflammatory site, and macrophage maturation (55, 56) . BTK is phosphorylated in two tyrosine sites (Y223 and Y551), and Syk and Lyn are known to be upstream to BTK in B cells (57) . Whether these kinases are involved in BTK actions in macrophages is unknown. Here, we showed that Syk inhibitor R406 did not prevent LTB4-mediated inflammasome, which suggests that Syk does not influence BTK actions in inflammasome actions. BTK classically activates PLC, PI3K/Akt, and NF-κB, which could, in turn, regulate the first signal (NF-κBdependent expression of inflammasome components) as well as the second signal (PI3K) and therefore, increasing NLRP3 phosphorylation and favoring inflammasome assembly.
However, PI3K inhibition does not prevent LTB4 effects on inflammasome assembly. These data suggest that LTB4 enhances inflammasome assembly by increasing the association between phosphorylated BTK with ASC. Future studies will be needed to determine the events upstream to BTK activation, as well as the ASC phosphorylation sites activated by BTK.
IL-1β is crucial for the control of S. aureus skin infection by controlling neutrophil migration to the site of infection and abscess formation (58) . We have demonstrated that LTB4 also enhances S. aureus clearance in the skin by increasing neutrophil migration and abscess formation (20) . We and others have shown that LTB4 enhances IL-1β, but here, we are providing further evidence that both IL-1β and LTB4 are part of a positive feedback loop required for optimal host defense. Importantly, it has been shown that LTB4 is produced as part of the inflammasome activation, an event called eicosanoid storm (59) . In preliminary experiments, when we infected the skin of caspase-1 and NLRP3 deficient mice, we did not observe a reduction in LTB4 levels (not shown), suggesting that LTB4 is both an initial key component of the IL-1β-dependent skin bacterial clearance and that LTB4 is also part of a continuous positive feedback loop to protect the skin from infection.
In summary, our data show that the prevention of exaggerated LTB4/BLT1 actions is a promising and potent therapeutic strategy to prevent overwhelming inflammatory response by inhibiting both transcriptional programs involved in the expression of inflammasome components as well as preventing the intracellular signals required for inflammasome assembly. On the other hand, the treatment with exogenous LTB4 is a promising candidate to increase both antimicrobial effector functions and inflammatory response in hard to treat infections. BLT1 -/-.
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